Pamela Russell

Positions
- Emeritus Professor, Head of Biomedical Imaging and Prostate Cancer Models, APCRC-Q
- Emeritus Professor, IHBI, QUT
- Adjunct Professor, Centre for Advanced Imaging, University of Queensland.
Related websites and profiles
Qualifications
- DipEd, Canberra University, Australia, 1979
- PhD, Autoimmunity, Sir Gustav Nossal, Walter & Eliza Hall Institute of Medical Research, Melbourne, 1968
- MSc, Autoimmunity, Sir Macfarlane Burnet, Walter & Eliza Hall Institute of Medical Research, Melbourne, 1965
- BSc, Science (Biochemistry/Microbiology) University of Melbourne, Australia, 1963
Biography
Emeritus Professor Russell, AM (PhD, Dip Ed) has built an international reputation for her work in urological cancers - in particular bladder and prostate cancers. In 2003, she was awarded Membership of the Order of Australia (AM) for her research on bladder and prostate cancer and, in 2015, she was made a fellow of the Australian Academy of Health and Medical Sciences, Limited.
Prof Russell has extensive expertise in establishing cell lines and rare xenografts from primary human tumours and generating urological cancer models, and collaborates widely, within Australia and overseas in USA and Europe. Her recent research focus has been on developing new methods for prostate specific-membrane antigen (PSMA) targeted imaging using 19F-MRI, and studying new biomarkers in exosomes, which may indicate/predict the response of CRPC to chemotherapy.
Nationally, she helped to initiate the Australian Genitourinary Oncology Group and the Prostate Cancer Foundation of Australia (PCFA) (of which she is a life member). From 2007 to 2010 Prof Russell served as an inaugural Director/Secretary of the Australasian Urological and Prostate Cancer Clinical Trials Group (ANZUP). She is also an Australian editor for Urological Research and a member of Movember’s Global Scientific Committee.
In 2006 she received a prize for outstanding research alumnus of Sydney’s Kolling Institute of Medical Research, was made a life member of the Australasian Gene Therapy Society in 2009, and in 2010, PCFA’s Prostate Cancer Researcher of the Year in Australia. She has also served on Movember’s Global Action Plan Scientific Committee (2010-14) and Research Advisory Committees.
She was Professor of Medicine, University of New South Wales (UNSW) and Director of the Oncology Research Centre at the UNSW School of Medicine at Prince of Wales Hospital, Sydney from 1992-2008.
- Read More ▼
-
After training in immunology at the Walter & Eliza Hall Institute of Medical Research in Melbourne with Sir Macfarlane Burnet and Sir Gustav Nossal, she changed her research focus to cancer in 1984, and with Dr Derek Raghavan, set up the Urological Cancer Research Unit at Sydney University.
She has procured >$35M in grants, has published >200 peer reviewed articles, as well as several reviews and book chapters, edited one book and co-authored six patents. She is currently funded by the NHMRC and Movember GAP programs.
Prof Russell has been on peer review committees for the National Health and Medical Research Committee (NHMRC), Cancer Council Australia, Cure Cancer Australia, and regularly reviews papers from international journals. She has delivered presentations or chaired sessions at numerous international prostate cancer meetings.
She has trained 13 Honours students, 7 BSc (Med) students, 3 Masters’ students, 14 PhD and 1 MD student and 31 post-doctoral fellows.
Awards and grants
Awards
2015 | Fellow of the Australian Academy of Health and Medical Science, Limited |
2010 | Inaugural Prostate Cancer Foundation of Australia Prize and Lecture for Outstanding Excellence |
2010 | Prostate Cancer Foundation of Australia's Researcher of the year |
2009 | Made Life Member, Australasian Gene Therapy Society |
2009 | Alban Gee Prize for best poster presentation at USANZ |
2007 | Member of the year, listed in Madison's Who's Who |
2006 | Made Honorary Life Member, Prostate Cancer Foundation of Australia |
2006 | Awarded prize for outstanding alumni of Kolling Institute of Medical Research (75th Jubilee) |
2005 | Listed in Marquis Who's Who in Medicine and Healthcare, USA |
2003-2005 | Listed in Who's Who, Australia |
2003 | Platinum Nomination for the CSIRO Chairman's medal. Gene Therapy: A new approach for treating prostate cancer |
2003 | Order of Australia (AM) for outstanding contributions to prostate and bladder cancer research |
1962 | Dunlop Rubber prize for Biochemistry |
1960 | Commonwealth Scholarship |
Grants
2017-2018 |
Translational Research Institute (TRI) Spore Grant $80,000 |
MicroRNA replacement therapy for indolent and aggressive prostate cancer. |
Batri J, Russell PJ, Vela I, Cristina A |
2016-2018 |
National Health and Medical Research Council (NHMRC) Category 1 APP108043 $633,757 |
Immunopolymeric drugs for prostate cancer therapy |
Thurecht K, Russell PJ, Mahler S, Boyd A, Howard C (AIs: Thompson L, Heathcote P, Straw R). |
2016-2018 |
NHMRC Category 1 APP 108043 $541,000 |
The Microniche: A novel in-vitro and in-vivo prostate cancer model system |
Doran MR, Vela I, Tse B, Russell PJ (AIs Pettit A, Wang C, Clements JA). |
2015-2017 |
Australian Research Council (ARC) Linkage LP150100703 $360,000 |
Next generation hybrid nanomaterials: investigating anti-PET as a component in bispecific antibodies as a novel biomolecule couple technology |
Thurecht KJ, Mahler S, Russell PJ, Walsh D, Campbell. |
2015-2017 |
Prostate Cancer Foundation of Australia (PCFA) / Movember Foundation $3,250,000
|
Movember Revolutionary Team Award 3: Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer. |
Butler L,Collaborators: Tilley W, Hoy A, Wittert G, Nelson CC, Scott A, Swinnen J, Clayton A,Weickhardt A, Davis I, Power C, Bianco-Miotto T, Russell PJ (AI), Brooks D, Sutherland P, Parnis F |
2015-2017 |
NHMRC Development Grant Category 1 APP1093539 $700,000 |
Novel prostate cancer target for diagnosis, imaging, detection of recurrence and response to therapy |
Nelson CC, Russell PJ, Walsh BJ, Campbell D. |
2014-2017 |
PCFA Movember Revolutionary Team Award $4,250,000 |
Adaptive response to androgen targeted therapies: A strategic offensive on resistance |
Nelson CC, et al. (AIs, include PJ Russell). |
2015-2016 |
World Cancer Research (Former AICR), 103624 pounds ~$168,907 |
A humanized in vivo model to test novel therapeutic strategies against prostate cancer bone metastasis. |
Hutmacher D, Denham J, Russell PJ, Williams ED, Levesque J-P, Holzapfel BA. |
2015 |
ARC – Linkages, Infrastructure and Equipment Fund (LIEF) Category 1 LEIF 50100067 $390,000 |
The Vevo 2100 Micro-ultrasound plus LAZR Photoacoustic Imaging Platform |
Russell PJ, Gobe G, Herington A, Langton C, Thurecht K, Brereton I, Frazer I, Fielding A, Hutmacher D, Hill M |
2015 |
Australian Cancer Research Foundation (ACRF) $4 million ($2.5 m obtained) |
ACRF Facility for Molecular Imaging Agents (AFMIAC) |
Reutens D, Cooper MA, Smith MT, Boyd A, Richards L, Bartlett PF, Russell PJ, Walker DG, Bhalla R, Barth M, Palmeri C, Thurecht K, Venkatachalam T, Allavena R, Straw R, Tesiram Y, Bunt J, Francois M, Osborne G. |
2014-2015 |
PCFA/Movember Foundation |
Movember Global Action Plan Xenograft Project Grant |
Williams ED, Russell PJ, Nelson C |
2014 |
TRI Inter-Institutional Collaborative Research Funding Award $25,000 |
Diagnosing small renal masses; solving the clinical problem of how best to manage patients with kidney neoplasms that are not life threatening |
Gobe G, Wood S, Coward J, Russell PJ, Saunders N, Lott W (AI Hemamali Samaratunga). |
2014-2015 |
Movember Xenograft project Grant $112,000 |
Global Action Plan-Xenografts) |
Williams ED, Russell PJ, Nelson CC |
2014-2015 |
Gallipoli Medical Research Foundation $50,000 |
Evaluation of PSMA-based positron emission tomography and magnetic resonance imaging for detection of multiple cancer foci in localized prostate cancer patients. |
Heathcote P, Thomas P, Wood S, Greenslade S, Lampe G, Shephard B, Nelson CC, Russell PJ |
2013-2017 |
Australian Government Department of Health and Aging $6,163,000 |
Australian Prostate Cancer Research Centre – Queensland |
Nelson CC, Clements J, Russell PJ, Herington A, Chopin L, Hutmacher D, O’Byrne K, Graves N, Yates P, Williams ED, Richard D, Wood S, Vela I, Heathcote P, Lehman M, Gogna K, McCaffrey E, Greenslade S, Lampe G, Shepherd B. |
2013-2014 |
Movember Global Exosome Biomarker Project Grant $227,000 |
Development of assays for the capture and detection of prostate cancer-derived exosomes and exosomal markers. |
Russell PJ, Soekmadji C, Nelson CC, Hovens C. |
2013-2016 |
NHMRC APP1046831 Category 1 $545,362 |
Imaging for prostate cancer theranostics |
Russell PJ, Whittaker A, Thurecht K (AIs, Nelson C, Coswin G, Heston WD, Emberton M.) |
2012 |
PCFA NDDA0411 $100,000
|
Simultaneous imaging and drug delivery for prostate cancer theranostics |
Russell PJ, Whittaker A, Thurecht K, Heston WW. |
2012-2015 |
NHMRC APP1031228 Category 1 $606,134 |
Identification of PACE-1 as a novel therapeutic target for the treatment of prostate cancer |
Ling, MT, Quinn R, Russell PJ, (AI: Nelson, C) |
2011 |
ARC - LIEF Category 1 $330,000 |
Comprehensive Cell Imaging Facility |
Clements J, McMillan N, Whitehead JB, Beagley KW, Russell PJ, Nelson CC, Hutmacher DW, Atkinson MK, Dawson PA, Frazer IH, Gonda TJ, Hooper JD, Levesque JP J, McGuckin MA, Munster DJ, Rice AM, Thomas R, Vuckovic S, Waterhouse NJ. |
2011-2014 |
ARC Discovery Category 1 DP110103890 $436,000 |
Development and validation of virtual epithelial cancer models using an integrated modelling and experimental three-dimensional approach |
Hutmacher D, McElwain DL, Russell PJ, Flegg JA, Loessner D, Clements J, Dalton PD, Byrne HM. |
2011-2013 |
NHMRC APP1010141 Category 1 $596,306 |
KLK4 is a master regulator of tumour microenvironment remodelling in prostate cancer and bone metastasis |
Clements J, Nelson C, Hutmacher D, Russel PJ. |
2010-2011 |
Queensland Cancer Council 614273 $196,500 |
The role of KLK4 in prostate cancer progression |
Clements JA, Hutmacher DW, Nelson CC, Russell PJ. |
2010 |
PCFA $124,798 |
Targeted nanoparticles for imaging prostate cancer |
Russell PJ, Khatri A, Cowin G, Thierry B, Power C. |
2010 |
PCFA
|
Application for a Syngene G:Box Chemi XT unit |
Russell PJ, Nelson CC, Lin P, Clements JA, Harris J, Hooper J, Chopin L, Herington A, Stephenson SA. |
2009 |
Cancer Institute, NSW, Research Equipment Grant $300,000 |
Aperio Scan Scope Virtual Slide Scanner for collaborative cancer histopathology |
Hawkins N, Ward R, Apte M, Russell PJ, Sewell W. |
2008-2009 |
NHMRC Development Category 1 APP497290 $160,500 |
Potential therapeutic roles for a protease inhibitor |
Harris J, Clements J, Russell PJ. |
2008-2010 |
Cancer Australia and PCFA (NHMRC510239) $587,525. |
Preclinical evaluation of novel prostate-targeted nanoparticles for imaging primary and metastatic prostate cancer |
Rusell PJ, Amal R, Walsh BJ, Bucci J, de Souza P. Changed in 2009 to : Russell PJ, Thierry B, Walsh BJ, Bucci J, de Souza P, Khatri A. $584,000 |
2008 |
Goldstar Award, UNSW $40,000 |
Preclinical evaluation of novel prostate-targeted nanoparticles for imaging primary and metastatic prostate cancer |
Rusell PJ, Amal R, Walsh BJ, Bucci J, de Souza P. Awarded but not taken up as ARC Linkage successful |
2008-2010 |
ARC Linkage Grants LP0882720 $372,000 |
Numerical modelling and experimental studies to design and engineer nanoparticulate systems for bioapplications |
Amal R, Russell PJ, Walsh BJ, Gooding J. |
2008-2010 |
NHMRC APP510238 Category 1 $432,000 |
Combined novel tumour-targeted molecular and traditional chemotherapy for treating androgen refractory prostate cancer |
Russell PJ. |
2008-2010 |
UNSW Foundation & PCFA $300,000 |
Studies of bone metastasis from prostate cancer |
Russell PJ, Power C. |
2007 |
Cancer Inst. NSW, $240,200 |
Establishment of networking data base and animal support for live animal imaging |
Russell PJ, Khachigian L, Crowe PJ, Rae C, Wlash W, Haber M, Lock R, Yang j-lL, Tuch B, Rose M, Price W, Power C. |
2007 |
UNSW equipment grant $1,100,000 |
Major Research and Infra-structure equipment: Vevo and intra-vital microscopy |
Khachigian L, Chesterman C, Hogg P, Jessup W, Chong B, Kritharides L, Gaus K, Haber M, Norris M, Kavallaris M, Lock R, Brown AJ, Gooding J, Russell PJ, Power C, Amal R, Rose M, Geczy C, Morris M, Waite P, Ashwell K, Hill M, Carrive P, Stoodley M, Brew B, Tuch B, Kuldip S. |
2007 |
UNSW, Major Research and Infrastructure $476,000 |
MicroCT scanner |
Russell PJ, Waite P, Geczy C, Rose M, Khachigian L, Tuch B, Walsh W, Stoodley M, Yang J-L, Carrive P, Lovell N, Power C, Amal R. |
2007-2009 |
Cancer Council NSW $300,000 |
Secreted phospholipase A2 in prostate cancer |
Scott K, Graham G, Dong Q, Russell PJ. |
2007-2009 |
Cancer Council NSW $299,650 |
Chemo-sensitising pathways in ovarian cancer |
de Fazio A, Harnett P, Russell P, Associate Investigators: Bowtell D, Guminski A, Byth K, Sharma R. |
2007-2009 |
ARC - LIEF LP0774951 $75,000 |
Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis |
Li Y, Willcox MD, Cozzi PJ, Russell PJ, Walsh BJ, Zhao Z. |
2007-2009 |
Sydney Foundation of Medical Research $225,000 |
Studies of bony metastases |
Russell PJ, Power C |
2007-2009 |
UNSW Faculty of Medicine Strategic Initiatives Grant $300,000 |
Establishment of Biomedical Nanotechnology Centre |
Kavallaris M, Davis T, Khachigian LM, Norris M, Tuch B, Russell P, Cunningham A, Bulmus V. |
2006 |
MSW Cancer Institute: Equipment grant $300,000 |
Imaging system for live small animals (Xenogen IVIS 100 System) |
Russell PJ, Crowe PJ, Haber M, Khachigian L, Lock R, Ormandy C, Rose M, Bucci J, Yang J-L, Power C, Khatri A, Kavallaris M, Rawlinson W. |
2006-2007 |
Novartis $130,000 |
Inhibition of bony metastases by therapeutic agents from Novartis (alone and in combination) using prostate cancer RM-1(BM)GFP metastasis model in immunocompetent mice |
Power C, Russell PJ |
2006-2008 |
NSW Cancer Council $375,000 |
The role of the TGF-b superfamily cytokine MIC-1 in the biology of cancer |
Breit S, Russell PJ |
2005 |
Prince of Wales Clinical School Research Enhancement Grant $13,000 |
The significance of mutations in the FGFR3 gene to bladder cancer progression. |
Jackson P, Russell PJ, Hung T-T, Roscioli T. |
2005 |
Prince Henry Centenary Foundation, & Children’s Hospital $500,000 |
Purchase of confocal microscope |
Cunningham A, Kavallaris M, Russell PJ |
2005 |
Prince of Wales Clinical School Research Enhancement Grant $13,000 |
Relationship of EGFR receptor mutation and gene variation in its signalling pathways to the synergistic effect of interferon-alpha plus erlotinib in treatment of human colon cancer cell lines. |
Goldstein D, Yang J-L, Russell PJ |
2005-2009 |
NSW Cancer Institute: Translational grant $3,750,000 |
Identification and validation of molecular markers of prognosis and therapeutic responsiveness in prostate cancer |
Clarke S, Henshall S, Russell PJ, Horvath L, Sutherland R, Kench J, Lee C-Soon, Molloy PL, Grygiel J, Stricker P, Boyer M. |
2005 |
NSW Cancer Institute: Research Infrastructure grant |
Infrastructure support for an established cancer genetics/genomics facility. |
Hayes V, Ormandy C, Breit S, Butt A, Clark S, Daly R, Grygiel J, Henshall S, Horvath L, Kaplan W, Kench J, Kohonen-Corish M, Musgrove E, O’Brien P, Russell PJ, Sutherland R, Ward RL. |
2005-2006 |
NSW Cancer Institute, Research Infrastructure grant $214,625 |
SESAHS Consortium for rational therapeutics |
Ward R, Links M, Goldstein D, Russell PJ |
2005 |
Rebecca Cooper Foundation $16,000 |
Purchase of a tissue slicer |
Katri A, Russell PJ |
2004-2006 |
Department of Veterans’ Affairs Australia $490,500 |
Oncogenic action and therapeutic potential of PLA2 in prostate cancer. |
Dong Q, Scott K, Graham G, Russell PJ |
2005 |
UNSW Faculty of Medicine Enhancement Grant $12,000 |
To purchase real time PCR. |
Russell PJ, Erlich J |
2004-2008 |
NHMRC Enabling Grant $2,100,000 |
Prostate Cancer Tissue Banking. |
Clements JA, Risbridger, V Marshall, D Roder, J Stahl, F Gardiner, D Nicol, M Frydenberg, J Pederson, P Stricker (PJ Russell AI) |
2004-2007 |
US Army Defense Department, USA W81XWH-1-004 New Investigator Award $300,000 |
Control of micrometastatic prostate cancer using multiple alpha targeted therapy |
Li Y, Cozzi PJ, Rizvi SMA, Diwan A, Allen BJ, Russell PJ |
2004 |
Prince of Wales Hospital Oncology Institute Grant $25,000 |
Studies of gene array of p53-expressing human prostate cancer cell lines |
Blair J, Russell PJ |
2004 |
Prince of Wales Hospital Oncology Institute Grant $42,000 |
Studies of chemotherapy and radiotherapy of prostate cancer |
Zhang AL, Milross C, Russell PJ |
2004 |
Prince of Wales Hospital Oncology Institute Grant $20,000 |
Top up for gene therapy work |
Russell PJ, Khatri A. |
2004 |
Cure Cancer Foundation of Australia $48,028 awarded but not taken up as Dr Zhao moved. |
Purification, identification and functional studies of proteases expressed in prostate cancer cell lines – a functional proteomic study |
Zhao J, Russell PJ |
2004 |
Faculty of Medicine, Enhancement grant UNS $15,000 |
To purchase fluorescence microsopy imaging equipment |
Russell PJ, Erhlich J. |
2004 |
Clive and Vera Ramaciotti $29,878 |
Microscopy equipment |
Erlich J, Russell PJ |
2004 |
NHMRC equipment grant $60,000 |
Purchase of fluorescence microscopy imaging equipment |
Russell PJ, Erlich J |
2003 |
Cure Cancer Foundation $60,000 |
Purchase of a faxitron |
Broan JM, Russell PJ |
2003-2005 |
National Institute of Health and National Institute of Diabetes and Digestive and Kidney Diseases Bethesda DK067681-01 US $216,000 (~A$342,857) |
The role of IL18 in the spread of prostate cancer to the bone |
Russell PJ, Martiniello-Wilks R, Zhang A. |
2003-2005 |
Department of Defense, US Army, Alternative Funding DAMD17-02-1-0107 US$522,000 (~A$900,000) |
Formulated delivery of enzyme/pro-drug and cytokine gene therapy to promote immune reduction of treated and remote tumors in mouse models of prostate cancer. |
Russell PJ, Both GW, Molloy PL and others from CSIRO |
2002-2004 |
Department of Defense, US Army, New Idea Award DAMD17-02-1-0108 US$456,000 (~A708,592) |
Studies of the role of p53 mutations in metastases of prostate cancer to bone. |
Russell PJ, Brown JM |
2004 |
Sydney Foundation for Medical Research $151,000 |
Studies of prostate cancer |
Russell PJ |
2002-2003 |
Sydney Foundation for Medical Research $176,000 |
Studies of proteases in prostate cancer |
Russell PJ, Zhao Z |
2001 |
Australian Kidney Foundation, Equipment grant $13,224 |
Equipment grant |
Russell PJ |
2001 |
Clive and Vera Ramaciotti Foundation $15,831 (equipment) |
Identification of proteases associated with prostate cancer invasion and progression |
Daja M, Russell PJ |
1999-2003 |
FH Faulding support for CSIRO, SESAHS And AusIndustry Start Plus, Funds for ORC, POWH: $1,220,380 |
Studies of gene therapy |
Russell PJ and team |
2000-2001 |
Sydney Foundation for Medical Research $248,424 |
Studies of proteases produced by prostate cancer cells, (includes equipment) |
Russell PJ, Daja M |
1998-2001 |
AusIndustry grant, for CSIRO, CSL and SESAHS $1,000,000 |
Lytic peptides for cancer therapy |
CSL, CSIRO, Russell PJ teams |
1999 |
Australasian Urological Foundation $20,000 |
Cytodine methylation of regulatory sequences near glutaehione-S transferase gene in the peripheral blood of patients with prostate cancer |
Russell PJ, Patel M |
1999 |
Leo and Jenny Leukaemia and Cancer Foundation $49,489 |
The role of KAI-1 in invasive bladder cancer. |
Jackson P, Russell PJ |
1999-2001 |
NHMRC APP990152 $315,000 Category 1 |
Therapy for prostate cancer using the prostate specific membrane antigen for targeting |
Russell PJ, Molloy PL, Both GW, Jackson P |
1998-1999 |
NSW Cancer Council $150,000 Category 1 |
Gene therapy for androgen-independent prostate cancer: Preclinical Studies |
Russell PJ, Molloy PL, Both GW |
1997-1999 |
Sydney Foundation for Medical Research $357,270 |
The relationship between protease activity and onset and progression. |
Russell PJ, Whittaker R. |
1996 |
Leo and Jenny Leukaemia and Cancer Foundation $5000 |
The role of KAI-1 as an inhibitor of metastasis in human prostate cancer |
Russell PJ, Glover H |
1996-1997 |
Workcover NSW ~$150,000 |
Validation of a monoclonal antibody test for the early detection of bladder cancer |
Russell PJ1 Kingsley E, Yu Y |
1996-1998 |
NSW Cancer Council $156,000 |
Methylation of tumour suppressor and tumor related genes in prostate cancer. |
Clark S, Molloy PL, Russell PJ |
1995-1997 |
NHMRC Category 1 $294,000 |
A predictive assay for radiotherapy response in bladder cancer |
Russell PJ, Braithwaite AW |
1995-1997 |
NHMRC Category 1 $311,322 |
Prostate cell specific expression of a toxin gene delivered by recombinant adenovirus vectors |
Russell PJ, Molloy PL, Both GW. |
1995-1997 |
NSW Cancer Council Category 1 $175,500 |
Cellular mechanisms involved in the development of androgen-independence and metastases of prostate cancer |
Russell PJ, Brown J |
1994-1995 |
AINSE $6,000 |
Low dose irradiation of human bladder tumours |
Russell PJ |
1994 |
Leo and Jenny Cancer and Leuaemia Foundation of Australia $40,784 |
Improved targeting of platinum anticancer drugs in breast and genitourinary tumours |
Russell PJ, Hambley T, McKeage M. |
1993 |
Clive and Vera Ramaciotti Foundation $15,000 |
Monoclonal antibodies for the treatment of bladder cancer |
Russell PJ |
1992 |
Prince Henry Hospital Centenary Research Fund $25,000 |
Autocrine growth factor interactions in human bladder cancer |
Russell PJ, Brown JL, Nash AR. |
1992 |
Department of Health $35,000 |
Care and maintenance of a nude mouse facility |
Russell PJ, Vincent PC. |
1991-1994 |
AMRAD $900,000 |
Therapeutic studies of human bladder cancer using monoclonal antibodies |
Russell PJ, Garsia R, Person B, Pearce N, Raghavan D. |
1991 |
University of Sydney Cancer Research Fund $28,000 |
Nude mouse consortium: Maintenance of nude mice for use in cancer research |
Russell PJ |
1991 -1992 |
AMRAD $83,000 |
Use of monoclonal antibodies for the diagnosis of human bladder cancer |
Russell PJ, Walker KZ, Garsia R, Raghavan D |
1991-1992 |
Worksafe Australia $90,000 |
Screening of voided urine for occupational bladder cancer |
Garsia R, Russell PJ, Kenyon R, Pearson B. |
1991 |
Royal Prnce Alfred Hospital Medical Fund $22,000 |
Cellular and Molecular studies of human bladder and prostate cancer. |
Russell PJ, Raghavan D. |
1991 |
Leo and Jenny Leukaemia & Cancer Foundation of Australia $46,535 |
Analysis of expression and mutations of p53 and fms genes in urine cells of cancer patients. |
Russell PJ, Grimmond S. |
1991-1993 |
NHMRC Category 1 $139,783 |
Significance of abnormal expression or mutation of genes in bladder cancer |
Russell PJ, Rozinova E, Grimmond S. |
1990-1991 |
NHMRC Category 1 $82,196 |
Experimental studies of heterogeneity of response to chemotherapy in bladder cancer |
Raghavan D, Bell D, Russell PJ, Foo T. |
1990 |
Australian Kidney Foundation (equipment) $5,000 |
Development of nude rat xenograft models for studies of intravesical therapy of human bladder cancer using radiolabelled monoclonal antibodies. |
Russell PJ |
1990 |
Leo and Jenny Leukaemia & Cancer Foundation of Australia $15,000 (equipment) |
Predicting response of bladder cancer to anti-cancer drugs |
Russell PJ, Raghavan D. |
1990 |
University of Sydney Cancer Research Fund $30,000 |
Diagnosis and therapy of human bladder cancer monoclonal antibodies |
Walker KZ, Russell PJ |
1990 |
University of Sydney Cancer Research Fund $26,000 |
Maintenance of nude mice for use in cancer research |
Russell PJ, Raghavan D, Basten A, Mountford C. |
1989 |
University of Sydney Cancer Research Fund $15,000 |
Maintenance of nude mice for cancer research |
Nude mouse consortium (convenor PJ Russell). |
1988 |
University of Sydney Cancer Research Fund $23,000 |
Diagnosis and management of human bladder carcinomas using murine monoclonal antibodies |
Walker KZ, Russell PJ |
1988 |
Leo and Jenny Leukaemia & Cancer Foundation of Australia $22,000 |
Salary for animal house attendant |
Nude mouse consortium (convenor PJ Russell). |
1988 |
Leo and Jenny Leukaemia & Cancer Foundation of Australia $29,546 (equipment) |
Development of metastasis and invasion of human solid tumours |
Russell PJ, Grant A |
1988-1990 |
NHMRC Category 1 $212,796 |
Studies of gene expression, rearrangement and mutation in urogenital cancers. |
Russell PJ, Raghavan D |
1986 |
NSW State Cancer Council Category 1 $12,424 |
Protein chemistry of phenotypic variants of prostate cancer |
Raghavan D, Russell PJ |
1986 |
NSW State Cancer Council Category 1 $25,000
|
Small cell undifferentiated carcinoma of the prostate: a model of tumour heterogeneity and studies of polypeptide hormone production. |
Raghavan D, Russell P, Russell PJ |
1986-1987 |
NHMRC Category 1 $114,469 |
Heterogeneity and differentiation of cancers of the genitourinary tract |
Raghavan D, Russell PJ, Vincent PC. |
Prof Russell has procured more than $36 million in grants, has published more than 200 papers in international journals (H factor 53), and has co-authored six patents.
Research interests
prostate cancer, nanoparticles for imaging and delivery of chemotherapy, gene therapy for late stage prostate cancer, exosomes (small vesicles secreted by cancer cells), origin of cancer cells, identifying biomarkers from protein, miRNA, RNA, DNA or lipid content, animal models of prostate cancer, targeted gene therapy,chemotherapy, castrate resistant prostate cancer, and bony metastasis
Top publications
Of 220 papers, 1 book , editor of 1 book, 19 book chapters...
- Russell PJ, Hicks JD, Burnet FM. Cyclophosphamide treatment of kidney disease in (NZB x NZW)F1 mice. Lancet, 1966; June 11, 287(7450):1279‑84 (Leading article). PMID: 4160875 (121 citations, Google Scholar). This paper describes the first use of cyclophosphamide for potentially treating systemic lupus erythematosus (SlE) in an animal model of disease. Cyclophosphamide is still used clinically to treat cases of SLE that are refractory to steroid therapy.
- Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja R, Vincent PC. Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res, 1986; 46(4 Pt2):2035‑40. PMID: 2418959. This paper describes the establishment of a series of patient derived xenografts of human bladder cancer, shows that these are extremely heterogeneous with respect to flow cytometry, and histology, and indicates for the first time effective treatment using carboplatin, which has subsequently been adopted into the clinic.
- Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer: advances and innovations. N Eng J Med, 1990; 322(16):1129-38 Reply: N Eng J Med, 1991; 324:126. PMID: 2181313. This classic paper provided expert information about management and biology of bladder cancer.
- Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ. Cytosine Deaminase-Uracil Phosphoribosyl Transferase and Interleukin-12 and -18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 2009;15(7):2323-2234. PMID19318483. This paper shows that gene therapy and immunotherapy are synergistic against prostate cancer.
- Pearce A, Simpson JD, Fletcher NL, Houston ZH, Fuchs, Whittaker AK, Russell PJ, Thurecht KJ. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic. Biomaterials, 2017;141:330-339. PMID:8711780 https://doi.org/10.1016/j.biomaterials.2017.07.004. This work uses a theranostic targeted to prostate cancer using a small molecule that binds to prostate specific membrane antigen. Both imaging and tumour regression were obtained.
Collaborators
- Dr Warick D Heston, Lerner Institute, Cleveland Clinic, USA
- Prof Andrew Whittaker and Dr Kristofer Thurecht, Australian Institute of Biotechnology and Nanotechnology, University of Queensland
- Dr Benjamin Thierry, Ian Wark Institute, University of South Australia
- Dr Jonathan Harris, Institute of Health and Biomedical Innovation, QUT
- Dr David MacFarlane, FRACP, Director, Queensland Positron Emission Tomography Service, Deputy Director, Nuclear Medicine, Royal Brisbane & Women's Hospital, Queensland
- Prof Andrew Boyd and Dr Jennifer Ellacott, Queensland Institute of Medical Research
- Dr Michelle Hill, Diamantina Institute, University of Queensland
Professional memberships and associations
Membership of Professional Societies
Current | Urological Society of Australasia: Associate Member |
Current | Gene Therapy group now Honorary Life member, Australian Society for Gene Therapy |
Current | Associate member of American Association for Cancer Research |
1991-2010 | Member of Clinical Oncology Society of Australia |
1993-2000 | Founding Member, Genitourinary Cancer Urological Group |
1998-1999 | Vice-Chairman, Genitourinary Cancer Urological Group |
1966-1995 | Member of Australian Society for Immunology |
1998 | Executive Member, Australian Society for Gene Therapy |
2007-2010 | Secretary and Director, ANZUP Australian and New Zealand Prostate and Urological Cancer Clinical Trials Group Ltd |
1995-2003 |
Founding member, and Director, Prostate Cancer Foundation of Australia |
1995-2000 |
Peer review Committee, Prostate Cancer Foundation of Australia |
2007 on |
Member, Scientific Advisory Committee, ANZUP |
2007 on |
Member, Scientific Advisory Committee, ANZUP Prostate Cancer |
Leadership in Professional Societies and Associations
1977-1978 | Qualifications Committee of the Austrlaian Society of Microbiology |
1979 | Education Officer of the Australian society of Microbiology for ACT |
1991 | Member of Research Committee of COSA |
1993 | Founding member of Genitourinary Oncology Group GUOG |
1995-1996 | Secretary, GUOG |
1998-1999 | Vice-Chairman, GUOG |
1998 | Executive, Gene Therapy Group, NSW |
1998-2000 | Board Member, Prostate Cancer Research Foundation |
2002- | Member of Bioresource Committee, APCC |
2004- | Executive Member, APCC |
2002-2004 | Member of Board of Management of Biological Resources Centre (BRC), UNSW |
2004-2006 | Member of Advisory Committee of Biological Resources (BRAAG), UNSW |
2004- | Member of IP Committee, St Vincents Hospital, Sydney |
2003-2006 | Member of Cancer Care Committee, South Eastern Sydney Area Health Service |
2005-2006 | Executive member, Scientific steering Committee, Prostate Cancer Foundation of Australia |
2006- | Executive Member, Urological Oncology Program, NSW Cancer Institute |
2007-2010 | Secretary, Director, Australian Prostate and Urological Cancer Clinical Trials Group, ANZUP, |